ArticleEuropean radiology experimental2026
Ultrasound-enhanced fine-needle aspiration biopsy improves yield of solid benign parotid gland tumor tissue: a pilot study.
Article in European radiology experimental, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
objectivesFine-needle aspiration biopsy (FNAB) and core-needle biopsy (CNB) are common methods to evaluate the pathology of an abnormal tissue mass. However, both methods have their limitations, e.g., FNAB samples often remain inadequate, and CNB is more invasive. A novel device, ultrasound-enhanced fine-needle aspiration biopsy (USeFNAB), can collect samples with greater cellular content quantitatively without compromising tissue quality. The purpose of this prospective study was to evaluate USeFNAB for the first time in humans in vivo. MATERIALS AND
methodsThis is a pilot study without any deviation from the contemporary management of the salivary gland tumor. Ten adult patients with a solid benign parotid gland tumor diagnosed by FNAB or CNB. Before parotidectomy, the tumors were sampled under ultrasound guidance with three different needle sampling techniques: USeFNAB, FNAB, and CNB. The influence of USeFNAB on the quantity and quality of the samples was investigated and compared with FNAB and CNB.
resultsThe quality of the cytological slides and histological tissue samples was similar in all samples obtained by USeFNAB, FNAB, and CNB. With USeFNAB, the mass increased on average by 1.6 and 3.4 times and the histological sample area by 1.7 and 3.4 times, as compared to FNAB and CNB, respectively.
conclusionThe results of this study demonstrated that USeFNAB seems to be a feasible and safe biopsy technique under in vivo conditions. In solid benign parotid gland tumors, USeFNAB increases sample yield as compared to conventional needle sampling methods, without affecting sample quality. RELEVANCE STATEMENT: USeFNAB could improve the diagnostic accuracy of needle biopsies and facilitate ancillary techniques such as molecular diagnostic studies.
trial registrationInstitutional permissions for the study were granted. The USeFNAB protocol went through risk analysis and mitigation for approval by the Finnish Medicine Agency (FIMEA) as an investigational device for research purposes (FIMEA/2023001788). KEY POINTS: USeFNAB showed an improved sample yield in solid benign parotid gland tumors compared to FNAB and CNB, without affecting sample quality. USeFNAB seems to be a feasible and safe biopsy technique. USeFNAB is a promising tool for improving the diagnostic accuracy of needle biopsies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.